Development of behavioral tolerance to Δ9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain

doi:10.1016/0091-3057(93)90546-6

Pharmacology Biochemistry and Behavior

Volume 46, Issue 3, November 1993, Pages 575-579

https://doi.org/10.1016/0091-3057(93)90546-6 Get rights and content

Abstract

The effect of repetitive administration of delta-9-tetrahydrocannabinol (Δ⁹-THC) in mice on behavioral and biochemical tolerance was determined in this study. Mice were injected twice daily with 10 mg/kg Δ⁹-THC for 6.5 days. On day 8, spontaneous activity was assessed or whole-brain homogenates were prepared for the cannabinoid receptor binding and mRNA studies. Although a twenty-sevenfold tolerance to Δ⁹-THC was observed in the behavioral assay, there was no significant alteration in receptor binding or mRNA levels.

References (15)

M.M. Bradford
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
Anal. Biochem.
(1976)
B.R. Martin et al.
Behavioral evaluation of cannabinoid analogs for agonistic antagonistic properties
Pharmacol. Biochem. Behav.
(1991)
T.M. Westlake et al.
Chronic exposure to Δ⁹-tetrahydrocannabinol fails to irreversibly alter brain cannabinoid receptors
Brain Res.
(1991)
P. Chomczynski et al.
Single step method of RNA isolation by acid guanidium thiocyanate phenol chloroform extraction
Anal. Biochem.
(1987)
E. Collin et al.
Neurobiological mechanisms of opioid tolerance and dependence
Clin. Neuropharmacol.
(1991)
D.R. Compton et al.
Cannabis dependence and tolerance production
A. DeLean et al.
Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves
Am. J. Physiol.
(1977)

There are more references available in the full text version of this article.

Cited by (85)

Mechanisms of cannabinoid tolerance
2023, Biochemical Pharmacology
Cannabis has been used recreationally and medically for centuries, yet research into understanding the mechanisms of its therapeutic effects has only recently garnered more attention. There is evidence to support the use of cannabinoids for the treatment of chronic pain, muscle spasticity, nausea and vomiting due to chemotherapy, improving weight gain in HIV-related cachexia, emesis, sleep disorders, managing symptoms in Tourette syndrome, and patient-reported muscle spasticity from multiple sclerosis. However, tolerance and the risk for cannabis use disorder are two significant disadvantages for cannabinoid-based therapies in humans. Recent work has revealed prominent sex differences in the acute response and tolerance to cannabinoids in both humans and animal models. This review will discuss evidence demonstrating cannabinoid tolerance in rodents, non-human primates, and humans and our current understanding of the neuroadaptations occurring at the cannabinoid type 1 receptor (CB₁R) that are responsible tolerance. CB₁R expression is downregulated in tolerant animals and humans while there is strong evidence of CB₁R desensitization in cannabinoid tolerant rodent models. Throughout the review, critical knowledge gaps are indicated and discussed, such as the lack of a neuroimaging probe to assess CB₁R desensitization in humans. The review discusses the intracellular signaling pathways that are responsible for mediating CB₁R desensitization and downregulation including the action of G protein-coupled receptor kinases, β-arrestin2 recruitment, c-Jun N-terminal kinases, protein kinase A, and the intracellular trafficking of CB₁R. Finally, the review discusses approaches to reduce cannabinoid tolerance in humans based on our current understanding of the neuroadaptations and mechanisms responsible for this process.
Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance
2020, European Neuropsychopharmacology
Citation Excerpt :
The results of these studies were interpreted to indicate that the development of behavioral tolerance to cannabis impairment involves a learning process and that prior training increases the rate of behavioral tolerance. A later study further indicated that behavioral tolerance to the impairing effects of cannabis on spontaneous activity of mice over one week of cannabis dosing did not alter CB1 receptor binding or mRNA levels (Abood et al., 1993), stressing the independent role of learning processes in the development of tolerance. Many experienced cannabis users share the conviction that they can volitionally control the effects of cannabis impairment (Albery et al., 2000; Greene, 2018; Tart, 1970).
Acute exposure to cannabis comes with neurocognitive impairment, leading to increased risk of human error and injury. Evidence however indicates that such acute effects are less prominent in chronic users, suggesting cannabis tolerance. Models of cannabis tolerance stress the importance of neurobiological or behavioral adaptations following repeated cannabis exposure. The pharmacodynamic model relates neuroadaptive changes in the brain to a blunted response to cannabis. Downregulation of CB1 receptors in chronic cannabis users has been associated with a normalization of dopaminergic output from the ventral tegmental area to the mesolimbic circuit, and a reduction of impairment during acute cannabis exposure. Such neuroadaptions are absent in occasional users, who show strong increments of dopamine and glutamate levels in the striatum, a loss of functional connectivity within the mesolimbic circuit and neurocognitive impairments when exposed to cannabis. Evidence for a behavioral model of cannabis tolerance that poses that users can have volitional control to overcome functional impairment during cannabis intoxication is relatively weak, and at best shows limited control over a limited number of behavioral functions. Cannabis tolerance is most likely to occur in users that consume high doses of cannabis continuously, at a high pace, for a prolonged period of time. Knowledge on frequency, dose and duration of cannabis use that is needed to achieve, maintain or lessen tolerance however is very limited, but will be of importance in the context of cannabis therapeutics and in legal settings when evaluating the impact of cannabis exposure on human function.
CB<inf>1</inf> and CB<inf>2</inf> Receptor Pharmacology
2017, Advances in Pharmacology
The CB₁ and CB₂ cannabinoid receptors (CB₁R, CB₂R) are members of the G protein-coupled receptor (GPCR) family that were identified over 20 years ago. CB₁Rs and CB₂Rs mediate the effects of Δ⁹-tetrahydrocannabinol (Δ⁹-THC), the principal psychoactive constituent of marijuana, and subsequently identified endogenous cannabinoids (endocannabinoids) anandamide and 2-arachidonoyl glycerol. CB₁Rs and CB₂Rs have both similarities and differences in their pharmacology. Both receptors recognize multiple classes of agonist and antagonist compounds and produce an array of distinct downstream effects. Natural polymorphisms and alternative splice variants may also contribute to their pharmacological diversity. As our knowledge of the distinct differences grows, we may be able to target select receptor conformations and their corresponding pharmacological responses. This chapter will discuss their pharmacological characterization, distribution, phylogeny, and signaling pathways. In addition, the effects of extended agonist exposure and how that affects signaling and expression patterns of the receptors are considered.
The influence of cannabinoids on learning and memory processes of the dorsal striatum
2015, Neurobiology of Learning and Memory
Extensive evidence indicates that the mammalian endocannabinoid system plays an integral role in learning and memory. Our understanding of how cannabinoids influence memory comes predominantly from studies examining cognitive and emotional memory systems mediated by the hippocampus and amygdala, respectively. However, recent evidence suggests that cannabinoids also affect habit or stimulus–response (S–R) memory mediated by the dorsal striatum. Studies implementing a variety of maze tasks in rats indicate that systemic or intra-dorsolateral striatum infusions of cannabinoid receptor agonists or antagonists impair habit memory. In mice, cannabinoid 1 (CB1) receptor knockdown can enhance or impair habit formation, whereas Δ⁹THC tolerance enhances habit formation. Studies in human cannabis users also suggest an enhancement of S–R/habit memory. A tentative conclusion based on the available data is that acute disruption of the endocannabinoid system with either agonists or antagonists impairs, whereas chronic cannabinoid exposure enhances, dorsal striatum-dependent S–R/habit memory. CB1 receptors are required for multiple forms of striatal synaptic plasticity implicated in memory, including short-term and long-term depression. Interactions with the hippocampus-dependent memory system may also have a role in some of the observed effects of cannabinoids on habit memory. The impairing effect often observed with acute cannabinoid administration argues for cannabinoid-based treatments for human psychopathologies associated with a dysfunctional habit memory system (e.g. post-traumatic stress disorder and drug addiction/relapse). In addition, the enhancing effect of repeated cannabinoid exposure on habit memory suggests a novel neurobehavioral mechanism for marijuana addiction involving the dorsal striatum-dependent memory system.
Cannabinoids and Epilepsy
2015, Neurotherapeutics
Cannabis has been used for centuries to treat seizures. Recent anecdotal reports, accumulating animal model data, and mechanistic insights have raised interest in cannabis-based antiepileptic therapies. In this study, we review current understanding of the endocannabinoid system, characterize the pro- and anticonvulsive effects of cannabinoids [e.g., Δ9-tetrahydrocannabinol and cannabidiol (CBD)], and highlight scientific evidence from pre-clinical and clinical trials of cannabinoids in epilepsy. These studies suggest that CBD avoids the psychoactive effects of the endocannabinoid system to provide a well-tolerated, promising therapeutic for the treatment of seizures, while whole-plant cannabis can both contribute to and reduce seizures. Finally, we discuss results from a new multicenter, open-label study using CBD in a population with treatment-resistant epilepsy. In all, we seek to evaluate our current understanding of cannabinoids in epilepsy and guide future basic science and clinical studies.
The behavioral effects of acute Δ<sup>9</sup>-tetrahydrocannabinol and heroin (diacetylmorphine) exposure in adult zebrafish
2014, Brain Research
Citation Excerpt :
For example, acute exposure to THC stimulates larval locomotion at low concentrations and lowers it at high doses, a response ameliorated by a CB1 antagonist Am-251 (Akhtar et al., 2012, 2013). Larval zebrafish chronically exposed to THC demonstrate tolerance with normal locomotor behavior without sedation (Akhtar et al., 2013), which generally parallels rodent observations (Barnes and Fried, 1974; Abood et al., 1993; Viveros et al., 2005; Lafenetre et al., 2007). Complementing larval models, adult zebrafish are also becoming widely used in psychopharmacology and drug abuse research (Kily et al., 2006; Bencan et al., 2009; Gerlai et al., 2009a; Blaser et al., 2010; Grossman et al., 2010; Stewart A. et al., 2010a, 2011c).
The use of psychotropic drugs in clinical and translational brain research continues to grow, and the need for novel experimental models and screens is becoming widely recognized. Mounting evidence supports the utility of zebrafish (Danio rerio) for studying various pharmacological manipulations, as an alternative model complementing the existing rodent paradigms in this field. Here, we explore the effects of acute 20-min exposure to two commonly abused psychotropic compounds, Δ⁹-tetrahydrocannabinol (THC) and heroin, on adult zebrafish behavior in the novel tank test. Overall, THC administration (30 and 50 mg/L) produces an anxiogenic-like reduction of top swimming, paralleled with a slower, continuous bottom swimming. In contrast, heroin exposure (15 and 25 mg/L) evoked a hyperlocomotor response (with rapid bouts of bottom swimming and frequent ‘bouncing’ motions) without altering anxiety-sensitive top/bottom endpoints. The behavioral effects of these two compounds in zebrafish seem to parallel the respective rodent and human findings. Collectively, this emphasizes the growing significance of novel emerging aquatic models in translational drug abuse research and small molecule screening.

View all citing articles on Scopus

View full text

Development of behavioral tolerance to Δ9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain

Abstract

Anal. Biochem.

Pharmacol. Biochem. Behav.

Brain Res.

Single step method of RNA isolation by acid guanidium thiocyanate phenol chloroform extraction

Anal. Biochem.

Neurobiological mechanisms of opioid tolerance and dependence

Clin. Neuropharmacol.

Cannabis dependence and tolerance production

Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves

Am. J. Physiol.

Development of behavioral tolerance to Δ⁹-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain